Evidence map›Paper›PMID 11444427›Full record

ArticleEndocrine2001

Effect of 1alpha,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo.

D D Dean, B D Boyan, Z Schwart, O E Muniz, M R Carreno, S Maeda, D S Howell

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

D D DeanDepartment of Orthopaedics, University of Texas Health Science Center at San Antonio, 78229-3900, USA. deand@uthscsa.edu
B D Boyan
Z Schwart
O E Muniz
M R Carreno
S Maeda
D S Howell
The University of Texas Health Science Center at San Antonio · USUniversity of Miami · USMiami VA Healthcare System · US

Funding

ROLE OF BONE FACTORS IN ENDOCHONDRAL OSSIFICATIONR01DE008603 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI BOYAN, BARBARA D. · 1989 to 2001
$829k
ROLE OF MEMBRANES IN MINERALIZATION OF BONES AND TEETHR01DE005937 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI BOYAN, BARBARA D. · 1985 to 2001
$514k
ROLE OF PHOSPHOLIPIDS IN MINERALIZATION OF OSTEOIDR01AR008662 · NIAMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HOWELL, DAVID S · 1986 to 1992
–
ROLE OF PHOSPHOLIPIDS IN MINERALIZATION OF OSTEOIDR37AR008662 · NIAMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HOWELL, DAVID S · 1993 to 1999
–
NIAMS NIH HHS AR-08662NIDCR NIH HHS DE-05937NIDCR NIH HHS DE-08603
6 · The paper itself

Abstract

Recent studies indicate that 1alpha,25-dihydroxyvitamin D3 (1alpha,25[OH]2D3) and 24R,25-dihydroxyvitamim D3 (24R,25[OH]2D3) differentially regulate proliferation, differentiation, and matrix synthesis of growth plate chondrocytes. To determine whether both metabolites play the same or different roles in vivo, we used the vitamin D-deficient rat as a model. Rickets was induced and then reversed by administering a single dose of ergocalciferol, 1alpha,25(OH)2D3, or 24R,25(OH)2D3 and euthanizing the animals after 4, 24, 48, or 72 h. Growth plates were either processed for histology and histomorphometry or extracted with buffered guanidine-HCl. Neutral metalloproteinase activity in the extracts was measured by use of aggrecan-containing beads, and collagenase activity was determined by use of radioactive type I collagen. The levels of tissue inhibitor of metalloproteinases (TIMP) and plasminogen activator were also determined. The morphology of the growth plate varied as a function of treatment. While 24R,25(OH)2D3 appeared to affect cell maturation and 1alpha,25(OH)2D3 appeared to affect terminal differentiation and calcification, response to ergocalciferol was indicative of the combined responses to the individual metabolites. Enzyme activity was regulated in a differential manner. Treatment with ergocalciferol produced a rapid decline in both neutral metalloproteinase and collagenase activities that was statistically significant by 4 h. By contrast, 1alpha,25(OH)2D3 had no effect on neutral metalloproteinase activity but caused a significant decrease in both active and total collagenase activity by 4 h, while 24R,25(OH)2D3 decreased neutral metalloproteinase activity by 48 h and had no effect on collagenase activity. Ergocalciferol had no effect on TIMP levels at any time examined, whereas 1alpha,25(OH)2D3 caused an increase at 48 and 72 h and 24R,25(OH)2D3 completely blocked TIMP production at 4 and 24 h. By contrast, plasminogen activator activity by ergocalciferol was decreased at 4 h, increased by 1alpha,25(OH)2D3 at 4 and 24 h, and decreased by 24R,25(OH)2D3 at all time points examined. These in vivo results confirm our previous cell culture observations showing that growth plate chondrocytes are differentially regulated by 1alpha,25(OH)2D3 and 24R,25(OH)2D3. Moreover, they show definitively that these two vitamin D metabolites play distinct roles not only in regulating neutral metalloproteinase and collagenase activities in growth plate cartilage but in cell maturation and calcification of this tissue in vivo.

Indexed as

24,25-Dihydroxyvitamin D 3AnimalsCalcitriolCartilageCell DivisionCollagenasesErgocalciferolsMaleMetalloendopeptidasesOrgan Culture TechniquesPlasminogen ActivatorsRatsRats, Sprague-DawleyRicketsTissue Inhibitor of Metalloproteinases24,25-Dihydroxyvitamin D 3CalcitriolCollagenasesErgocalciferolsMetalloendopeptidasesPlasminogen ActivatorsTissue Inhibitor of Metalloproteinases

Identifiers

PMID11444427
OpenAlexW2085943835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.